Brevan Howard Cuts Stake in Regeneron Pharmaceuticals

Hedge fund reduces position in biotech company by over 20% in Q3

Mar. 17, 2026 at 9:34am

Got story updates? Submit your updates here. ›

Brevan Howard Capital Management LP lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The hedge fund now owns 5,240 shares of the biopharmaceutical company's stock, valued at $2,946,000.

Why it matters

Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies. Changes in ownership by large institutional investors like Brevan Howard can signal shifts in market sentiment and influence the stock price.

The details

Brevan Howard sold 1,442 shares of Regeneron stock in the third quarter, reducing its total position to 5,240 shares. The hedge fund cited unspecified reasons for the sell-off, which represented a 21.6% decrease in its Regeneron holdings. Several other large investors also modified their positions in Regeneron during the quarter, with some increasing and others decreasing their stakes.

  • Brevan Howard reported the position change in its Q3 2026 13F filing.

The players

Brevan Howard Capital Management LP

A major hedge fund that has invested in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company that focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Regeneron's stock price and market position can be influenced by the investment decisions of large institutional investors like Brevan Howard. This latest reduction in the hedge fund's stake suggests a potential shift in sentiment around the biotech company, though the specific reasons behind the move remain unclear.